Hoefsmit, Esmée P.
The Netherlands Cancer Institute
2 papers on CoChatORCID 0000-0002-3989-8175
Most cited papers
- Verified
Susceptible loci associated with autoimmune disease as potential biomarkers for checkpoint inhibitor-induced immune-related adverse events
Hoefsmit, E. P., Rozeman, E. A., Haanen, J. B. A. G., & Blank, C. U. (2019) · ESMO Open
Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses
Cited by 29
- Verified
18-months relapse-free survival (RFS) and biomarker analyses of OpACIN-neo: A study to identify the optimal dosing schedule of neoadjuvant (neoadj) ipilimumab (IPI) + nivolumab (NIVO) in stage III melanoma
Rozeman, E. A., Menzies, A. M., Krijgsman, O., Hoefsmit, E. P., van de Wiel, B. A., Sikorska, K., Van, T. M., Eriksson, H., Bierman, C., Gonzalez, M., et al. (2019) · Annals of Oncology
Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management
Cited by 20
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free